Show simple item record

dc.contributor.authorVan der Ploeg, Catharina P B
dc.contributor.authorBlom, Maartje
dc.contributor.authorBredius, Robbert G M
dc.contributor.authorvan der Burg, Mirjam
dc.contributor.authorSchielen, Peter C J I
dc.contributor.authorVerkerk, Paul H
dc.contributor.authorvan den Akker-van Marle, M Elske
dc.date.accessioned2019-03-22T09:09:52Z
dc.date.available2019-03-22T09:09:52Z
dc.date.issued2019-02-25
dc.identifier.issn1432-1076
dc.identifier.pmid30805731
dc.identifier.doi10.1007/s00431-019-03346-3
dc.identifier.urihttp://hdl.handle.net/10029/622899
dc.description.abstractSevere combined immunodeficiency (SCID) is a condition that often results in severe infections and death at young age. Early detection shortly after birth, followed by treatment before infections occur, largely increases the chances of survival. As the incidence of SCID is low, assessing cost-effectiveness of adding screening for SCID to the newborn screening program is relevant for decision making. Lifetime costs and effects of newborn screening for SCID were compared to a situation without screening in the Netherlands in a decision analysis model. Model parameters were based on literature and expert opinions. Sensitivity analyses were performed. Due to earlier detection, the number of deaths due to SCID per 100,000 children was assessed to decrease from 0.57 to 0.23 and a number of 11.7 quality adjusted life-years (QALYs) gained was expected. Total yearly healthcare costs, including costs of screening, diagnostics, and treatment, were €390,800 higher in a situation with screening compared to a situation without screening, resulting in a cost-utility ratio of €33,400 per QALY gained.Conclusion: Newborn screening for SCID might be cost-effective. However, there is still a lot of uncertainty around the cost-effectiveness estimate. Pilot screening projects are warranted to obtain more accurate estimates for the European situation. What is Known: • Severe combined immunodeficiency (SCID) is a condition that often results in severe infections and death at a young age. • As the incidence of SCID is low, assessing cost-effectiveness of adding screening for SCID to the newborn screening program is needed. What is New: • Newborn screening for SCID is expected to reduce mortality from 0.57 to 0.23 per 100,000 children at additional healthcare costs of €390,800. The cost-utility ratio is €33,400 per QALY gained. • Due to large uncertainty around cost-effectiveness estimates, pilot screening projects are warranted for Europe.en_US
dc.language.isoenen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCost-effectiveness analysisen_US
dc.subjectDecision analysis modelen_US
dc.subjectNewborn screeningen_US
dc.subjectSevere combined immunodeficiencyen_US
dc.titleCost-effectiveness of newborn screening for severe combined immunodeficiency.en_US
dc.typeArticleen_US
dc.identifier.journalEur J Pediatr 2019; 178(5):721-9en_US
dc.source.journaltitleEuropean journal of pediatrics


This item appears in the following Collection(s)

Show simple item record